ESTs to *MAP3K13*: 186 (32,3 % of ESTs are tumor-specific)



ESTs to *asLZK*: 454 (82,7 % of ESTs are tumor-specific)

Fig.1


5′-end
RPL4 CAGAGTAATTCCAGGGATGTT // TCCTCATTATAGATGATGCACGGGCCC // TTGA
LOC158345 ·····G····· // ····· // ····
asLZK ····· // ····· // ·C··
22q13 ····A·····T···A····· // ··T·····G···C·····T··· // ··TG
LOC391135 ····· // ·····T·····T // ····
LOC646688 ····· // ····· // ····
14q11.2 ··T····· // ·····C·····G–·C···· // ·C··
2q33.1 ·····C·C····· // ·····C··GCA·····TAT· // ····
3′-end
RPL4 CTACCAAAGGAAGTTCAGGAAC // ATACGATGACCTTTAGACATG
LOC158345 ····· // ·····
asLZK A····· // ·····
22q13 ·C·····AA····· // ···T·····G·····
LOC391135 ····· // ····T·····T··
LOC646688 ·····A····· // ···T·····T·····
14q11.2 ·····G· // ·····C·····G·
2q33.1 ·C···G····· // ····A·····

Fig.2



PCR with non-differentiating primers

PCR with asLZK-specific primers

PCR with GAPDH-specific primers

3A



3B



Genomic site of ψRPL4 insertion

4A



4B